Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative products for diseases with unmet medical needs [6] - The company is listed on NASDAQ under the ticker BDRX [6] Upcoming Conference - Biodexa has been invited to present at the Emerging Growth Conference on February 19, 2025, at 09:40 AM Eastern time for a duration of 30 minutes [1][3] - The presentation will be led by CEO/CFO Stephen Stamp, who will also engage with the audience for questions [2] Product Pipeline - The company's lead development programs include: - eRapa, an oral tablet formulation of rapamycin for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer [6][7] - Tolimidone, a selective inhibitor of Lyn kinase for type 1 diabetes treatment [6][8] - MTX110, a formulation of the HDAC inhibitor panobinostat for aggressive rare/orphan brain cancer [6][9] Drug Delivery Technologies - Biodexa utilizes three proprietary drug delivery technologies aimed at enhancing the bio-delivery and bio-distribution of its medicines [10]
Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025